CN104799937A - 一种肾神经消融导管及其应用 - Google Patents
一种肾神经消融导管及其应用 Download PDFInfo
- Publication number
- CN104799937A CN104799937A CN201510038845.4A CN201510038845A CN104799937A CN 104799937 A CN104799937 A CN 104799937A CN 201510038845 A CN201510038845 A CN 201510038845A CN 104799937 A CN104799937 A CN 104799937A
- Authority
- CN
- China
- Prior art keywords
- nerve
- ablation
- electrode
- kidney
- sural
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002679 ablation Methods 0.000 title claims abstract description 128
- 210000005036 nerve Anatomy 0.000 title claims abstract description 113
- 210000001590 sural nerve Anatomy 0.000 claims abstract description 80
- 238000013507 mapping Methods 0.000 claims abstract description 55
- 238000012806 monitoring device Methods 0.000 claims abstract description 44
- 230000001588 bifunctional effect Effects 0.000 claims abstract description 15
- 210000003734 kidney Anatomy 0.000 claims description 64
- 230000008018 melting Effects 0.000 claims description 48
- 238000002844 melting Methods 0.000 claims description 48
- 238000012544 monitoring process Methods 0.000 claims description 42
- 230000004936 stimulating effect Effects 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 33
- 230000001537 neural effect Effects 0.000 claims description 22
- 239000000463 material Substances 0.000 claims description 21
- 230000000638 stimulation Effects 0.000 claims description 21
- 238000012545 processing Methods 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 5
- 230000010412 perfusion Effects 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 238000007405 data analysis Methods 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 230000006870 function Effects 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 12
- 210000002254 renal artery Anatomy 0.000 description 57
- 238000012360 testing method Methods 0.000 description 31
- 230000036772 blood pressure Effects 0.000 description 26
- 230000002889 sympathetic effect Effects 0.000 description 21
- 230000008859 change Effects 0.000 description 19
- 239000000155 melt Substances 0.000 description 15
- 230000035487 diastolic blood pressure Effects 0.000 description 10
- -1 polyethylene Polymers 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000002638 denervation Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 241000282898 Sus scrofa Species 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000004873 systolic arterial blood pressure Effects 0.000 description 6
- 239000004642 Polyimide Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 229920001721 polyimide Polymers 0.000 description 5
- 230000035488 systolic blood pressure Effects 0.000 description 5
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical group C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 102400000096 Substance P Human genes 0.000 description 4
- 101800003906 Substance P Proteins 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000005611 electricity Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 230000001734 parasympathetic effect Effects 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 229920002614 Polyether block amide Polymers 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 230000001053 orthosympathetic effect Effects 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 210000004345 peroneal nerve Anatomy 0.000 description 3
- 238000007674 radiofrequency ablation Methods 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- 239000004433 Thermoplastic polyurethane Substances 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 210000001617 median nerve Anatomy 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 230000007383 nerve stimulation Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000001179 pupillary effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229920002803 thermoplastic polyurethane Polymers 0.000 description 2
- 210000002972 tibial nerve Anatomy 0.000 description 2
- 210000000658 ulnar nerve Anatomy 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000013153 catheter ablation Methods 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Natural products CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- JLTCWSBVQSZVLT-UHFFFAOYSA-N n-[6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxa Chemical compound NCCCCC(C(=O)NCC(N)=O)NC(=O)C1CCCN1C(=O)C1NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC=2C=CC=CC=2)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(N)CSSC1.N1C(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 JLTCWSBVQSZVLT-UHFFFAOYSA-N 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920000052 poly(p-xylylene) Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 210000002979 radial nerve Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008660 renal denervation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Surgical Instruments (AREA)
Abstract
Description
Claims (15)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510038845.4A CN104799937B (zh) | 2014-01-27 | 2015-01-26 | 一种肾神经消融导管及其应用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410041071 | 2014-01-27 | ||
| CN2014100410716 | 2014-01-27 | ||
| CN201510038845.4A CN104799937B (zh) | 2014-01-27 | 2015-01-26 | 一种肾神经消融导管及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104799937A true CN104799937A (zh) | 2015-07-29 |
| CN104799937B CN104799937B (zh) | 2019-02-19 |
Family
ID=53685447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510038845.4A Active CN104799937B (zh) | 2014-01-27 | 2015-01-26 | 一种肾神经消融导管及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104799937B (zh) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018006383A1 (zh) * | 2016-07-07 | 2018-01-11 | 四川锦江电子科技有限公司 | 一种极间放电的消融装置 |
| CN109528297A (zh) * | 2018-10-29 | 2019-03-29 | 四川大学华西医院 | 一种可进行喉返神经监测的消融针及监测系统 |
| CN112336445A (zh) * | 2019-12-26 | 2021-02-09 | 上海微创电生理医疗科技股份有限公司 | 一种消融系统及其神经探测设备 |
| CN113133745A (zh) * | 2021-04-30 | 2021-07-20 | 中南大学湘雅二医院 | 一种交感神经链神经纤维定位标测装置 |
| CN116327347A (zh) * | 2023-03-01 | 2023-06-27 | 上海佰川声生命科技有限公司 | 一种消融导管 |
| CN119367037A (zh) * | 2023-07-26 | 2025-01-28 | 上海鸿电医疗科技有限公司 | 消融系统及其控制方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN201822910U (zh) * | 2010-06-04 | 2011-05-11 | 心诺普医疗技术(北京)有限公司 | 灌注式射频消融导管 |
| CN202637103U (zh) * | 2011-08-26 | 2013-01-02 | 王捷 | 具有肾神经标测功能的导管 |
| CN202982206U (zh) * | 2012-10-15 | 2013-06-12 | 陈平根 | 一种多极射频消融导管 |
| US20130253504A1 (en) * | 2012-03-21 | 2013-09-26 | Itzhak Fang | Flower catheter for mapping and ablating veinous and other tubular locations |
| CN103417290A (zh) * | 2012-05-14 | 2013-12-04 | 韦伯斯特生物官能(以色列)有限公司 | 用于血管消融的具有螺旋状端部的导管 |
-
2015
- 2015-01-26 CN CN201510038845.4A patent/CN104799937B/zh active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN201822910U (zh) * | 2010-06-04 | 2011-05-11 | 心诺普医疗技术(北京)有限公司 | 灌注式射频消融导管 |
| CN202637103U (zh) * | 2011-08-26 | 2013-01-02 | 王捷 | 具有肾神经标测功能的导管 |
| US20130253504A1 (en) * | 2012-03-21 | 2013-09-26 | Itzhak Fang | Flower catheter for mapping and ablating veinous and other tubular locations |
| CN103417290A (zh) * | 2012-05-14 | 2013-12-04 | 韦伯斯特生物官能(以色列)有限公司 | 用于血管消融的具有螺旋状端部的导管 |
| CN202982206U (zh) * | 2012-10-15 | 2013-06-12 | 陈平根 | 一种多极射频消融导管 |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018006383A1 (zh) * | 2016-07-07 | 2018-01-11 | 四川锦江电子科技有限公司 | 一种极间放电的消融装置 |
| CN109528297A (zh) * | 2018-10-29 | 2019-03-29 | 四川大学华西医院 | 一种可进行喉返神经监测的消融针及监测系统 |
| CN112336445A (zh) * | 2019-12-26 | 2021-02-09 | 上海微创电生理医疗科技股份有限公司 | 一种消融系统及其神经探测设备 |
| WO2021129027A1 (zh) * | 2019-12-26 | 2021-07-01 | 上海微创电生理医疗科技股份有限公司 | 一种消融系统及其神经探测设备 |
| CN113453637A (zh) * | 2019-12-26 | 2021-09-28 | 上海微创电生理医疗科技股份有限公司 | 一种消融系统及其神经探测设备 |
| CN112336445B (zh) * | 2019-12-26 | 2021-11-26 | 上海微创电生理医疗科技股份有限公司 | 一种消融系统及其神经探测设备 |
| CN113453637B (zh) * | 2019-12-26 | 2024-01-23 | 上海鸿电医疗科技有限公司 | 一种消融系统及其神经探测设备 |
| CN113133745A (zh) * | 2021-04-30 | 2021-07-20 | 中南大学湘雅二医院 | 一种交感神经链神经纤维定位标测装置 |
| CN116327347A (zh) * | 2023-03-01 | 2023-06-27 | 上海佰川声生命科技有限公司 | 一种消融导管 |
| CN119367037A (zh) * | 2023-07-26 | 2025-01-28 | 上海鸿电医疗科技有限公司 | 消融系统及其控制方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104799937B (zh) | 2019-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250072961A1 (en) | System and method for locating and identifying the functional nerves innervating the wall of arteries and catheters for same | |
| CN104799937A (zh) | 一种肾神经消融导管及其应用 | |
| CN102949176B (zh) | 肾神经消融术中肾神经分布标测方法及用于该方法的导管 | |
| CN101528123B (zh) | 用于诊断和/或治疗目的的区分和/或鉴定由靶神经支配的组织区域的系统和方法 | |
| CN115989000A (zh) | 用于识别和表征组织并为其提供靶向治疗的系统和方法 | |
| CN204814163U (zh) | 一种肾神经标测和消融导管及系统 | |
| US20160338773A1 (en) | Mapping and ablation of nerves within arteries and tissues | |
| US20200375658A1 (en) | Response monitoring | |
| JP2004065529A (ja) | 血圧制御装置 | |
| US20220104866A1 (en) | Systems and methods for therapeutic nasal treatment | |
| US9814521B2 (en) | Ablation catheter arrangement and method for treatment of a cardiac arrhythmia | |
| CN216456542U (zh) | 医疗导管、鞘管、导管组件及医疗系统 | |
| US20220104862A1 (en) | Systems and methods for therapeutic nasal treatment | |
| US20220104870A1 (en) | Systems and methods for therapeutic nasal treatment | |
| US20220104869A1 (en) | Systems and methods for therapeutic nasal treatment | |
| JP2023538953A (ja) | 治療用副鼻腔処置のためのデバイス |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 518118 Guangdong province Shenzhen Pingshan New District Industrial Zone planning five road No. 1 Applicant after: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. Address before: Baoan District Xixiang street Shenzhen city Guangdong province 518102 115 City District 1 factories Applicant before: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 518118, No. five, No. 1, great industrial zone, Ping Shan, Guangdong, Shenzhen Applicant after: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. Address before: 518118 Guangdong province Shenzhen Pingshan New District Industrial Zone planning five road No. 1 Applicant before: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 518118 No.1, Guihua 5th Road, Pingshan District, Shenzhen City, Guangdong Province Patentee after: Shenzhen Xinlitai Medical Equipment Co.,Ltd. Address before: 518118 No.1, Guihua 5th Road, Pingshan District, Shenzhen City, Guangdong Province Patentee before: SHENZHEN SALUBRIS BIOMEDICAL ENGINEERING Co.,Ltd. |